## Paul R Fortin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5878644/publications.pdf

Version: 2024-02-01

169 papers 14,559 citations

51 h-index 20307 116 g-index

172 all docs

172 docs citations

172 times ranked

14790 citing authors

#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism, 2001, 44, 2331-2337.	6.7	1,051
3	Outcomes of total hip and knee replacement: Preoperative functional status predicts outcomes at six months after surgery. Arthritis and Rheumatism, 1999, 42, 1722-1728.	6.7	637
4	Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nature Genetics, 2008, 40, 1059-1061.	9.4	534
5	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nature Genetics, 2009, 41, 71-76.	9.4	448
6	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391
7	Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis and Rheumatism, 2002, 46, 3327-3330.	6.7	357
8	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	5.8	314
9	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	3.0	249
10	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 863-868.	6.7	245
11	Validation of a meta-analysis: The effects of fish oil in rheumatoid arthritis. Journal of Clinical Epidemiology, 1995, 48, 1379-1390.	2.4	183
12	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 143.	1.6	180
13	"What do you expect? You're just getting older― A comparison of perceived osteoarthritis-related and aging-related health experiences in middle- and older-age adults. Arthritis and Rheumatism, 2006, 55, 905-912.	6.7	177
14	Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1550-E1559.	3.3	164
15	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.5	143
16	A Controlled Study of Diffuse Idiopathic Skeletal Hyperostosis Clinical Features and Functional Status. Medicine (United States), 1997, 76, 104-117.	0.4	142
17	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology, 2010, 49, 2172-2180.	0.9	142
18	Steroidâ€sparing effects of methotrexate in systemic lupus erythematosus: A doubleâ€blind, randomized, placeboâ€controlled trial. Arthritis and Rheumatism, 2008, 59, 1796-1804.	6.7	136

#	Article	IF	CITATIONS
19	Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 2011, 41, 203-211.	1.6	126
20	Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. Seminars in Arthritis and Rheumatism, 2012, 42, 179-185.	1.6	124
21	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2014, 73, 138-142.	0.5	115
22	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. Journal of Rheumatology, 2009, 36, 1200-1208.	1.0	111
23	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2013, 40, 831-841.	1.0	105
24	Recent corticosteroid use and recent disease activity: Independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. Arthritis and Rheumatism, 2008, 59, 169-175.	6.7	95
25	Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. Environmental Research, 2016, 146, 85-91.	3.7	94
26	Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1998, 11, 23-31.	6.7	93
27	Measuring relevant change: an emerging challenge in rheumatologic clinical trials. Arthritis and Rheumatism, 1995, 38, 1027-1030.	6.7	90
28	Measuring Clinically Important Changes With Patient-Oriented Questionnaires. Medical Care, 2002, 40, II-45-II-51.	1.1	88
29	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
30	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Seminars in Arthritis and Rheumatism, 2019, 49, 464-468.	1.6	79
31	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.5	78
32	The non-haemostatic role of platelets in systemic lupus erythematosus. Nature Reviews Rheumatology, 2018, 14, 195-213.	3.5	78
33	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 53, 609-612.	6.7	75
34	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. Quality of Life Research, 2005, 14, 1333-1344.	1.5	72
35	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
36	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70

#	Article	IF	Citations
37	Vasculitides associated with malignancy. Current Opinion in Rheumatology, 1996, 8, 30-33.	2.0	68
38	The role of stress in functional disability among women with systemic lupus erythematosus: A prospective study. Arthritis and Rheumatism, 1999, 12, 112-119.	6.7	67
39	The needs of patients with arthritis: The patient's perspective. Arthritis and Rheumatism, 1999, 12, 85-95.	6.7	67
40	Work disability in systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 378-385.	6.7	67
41	Quality of life in systemic lupus erythematosus patients during more and less active disease states: Differential contributors to mental and physical health. Arthritis and Rheumatism, 1999, 12, 401-410.	6.7	62
42	Systematic Review of Validation Studies of the Use of Administrative Data to Identify Serious Infections. Arthritis Care and Research, 2013, 65, 1343-1357.	1.5	62
43	The use of alternative medical therapies in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1410-1418.	6.7	60
44	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney International, 2011, 79, 914-920.	2.6	60
45	Infections in the lupus patient: perspectives on prevention. Current Opinion in Rheumatology, 2011, 23, 358-365.	2.0	60
46	Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 1275-1280.	1.5	60
47	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. Arthritis Care and Research, 2015, 67, 582-587.	1.5	60
48	Platelets release mitochondrial antigens in systemic lupus erythematosus. Science Translational Medicine, 2021, 13, .	5.8	59
49	The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs. Arthritis and Rheumatism, 2007, 57, 64-70.	6.7	58
50	Expanded Population of Activated Antigen-Engaged Cells within the Naive B Cell Compartment of Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2008, 180, 1276-1284.	0.4	55
51	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
52	Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environmental Research, 2015, 140, 474-478.	3.7	54
53	Comprehensive radiographic evaluation of diffuse idiopathicskeletal hyperostosis: Development and interrater reliability of a scoring system. Seminars in Arthritis and Rheumatism, 1998, 28, 88-96.	1.6	52
54	Counterbalancing patient demands with evidence: Results from a pan-canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Annals of Behavioral Medicine, 2002, 24, 88-99.	1.7	52

#	Article	IF	Citations
55	Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Research and Therapy, 2015, 17, 197.	1.6	52
56	Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. Rheumatology, 2016, 55, 2148-2155.	0.9	52
57	Evaluation of Clinical Outcomes and Renal Vascular Pathology among Patients with Lupus. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 757-764.	2.2	51
58	Distinct Subtypes of Microparticle-containing Immune Complexes Are Associated with Disease Activity, Damage, and Carotid Intima-media Thickness in Systemic Lupus Erythematosus. Journal of Rheumatology, 2016, 43, 2019-2025.	1.0	49
59	Costs of Rheumatoid Arthritis: New Estimates from the Human Capital Method and Comparison to the Willingness-to-Pay Method. Medical Decision Making, 2007, 27, 138-150.	1.2	46
60	Posterior Reversible Encephalopathy Syndrome: An Emerging Disease Manifestation in Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 2011, 41, 353-363.	1.6	46
61	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1426-1439.	1.0	43
62	Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Scientific Reports, 2019, 9, 4530.	1.6	43
63	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. Journal of Clinical Epidemiology, 2002, 55, 488-497.	2.4	42
64	Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1667-1672.	1.0	42
65	Unpacking Early Work Experiences of Young Adults With Rheumatic Disease: An Examination of Absenteeism, Job Disruptions, and Productivity Loss. Arthritis Care and Research, 2015, 67, 1246-1254.	1.5	42
66	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
67	Fatal pulmonary venoocclusive disease secondary to a generalized venulopathy: A new syndrome presenting with facial swelling and pericardial tamponade. Arthritis and Rheumatism, 1991, 34, 228-233.	6.7	41
68	Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus, 1999, 8, 660-670.	0.8	41
69	Development and initial validation of a selfâ€assessed lupus organ damage instrument. Arthritis Care and Research, 2010, 62, 559-568.	1.5	40
70	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. PLoS ONE, 2018, 13, e0196117.	1.1	40
71	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
72	Platelets Disseminate Extracellular Vesicles in Lymph in Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 929-942.	1.1	40

#	Article	IF	CITATIONS
73	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. Arthritis Care and Research, 2015, 67, 128-135.	1.5	39
74	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
75	Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. Journal of Autoimmunity, 2015, 58, 100-110.	3.0	38
76	Role of radiation therapy in patients with a diagnosis of both systemic lupus erythematosus and cancer. Arthritis and Rheumatism, 2005, 53, 67-72.	6.7	37
77	Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1270-1278.	6.7	37
78	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology, 2015, 54, 449-457.	0.9	37
79	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care and Research, 2019, 71, 134-141.	1.5	37
80	Reduced proportions of NKT cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Research and Therapy, 2008, 10, R108.	1.6	36
81	The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. Journal of Rheumatology, 2003, 30, 2385-91.	1.0	35
82	Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 254-261.	1.0	34
83	Healthcare Cost and Loss of Productivity in a Canadian Population of Patients with and without Lupus Nephritis. Journal of Rheumatology, 2011, 38, 658-666.	1.0	32
84	Increased Expression of B Cell Activation Factor Supports the Abnormal Expansion of Transitional B Cells in Systemic Lupus Erythematosus. Journal of Rheumatology, 2011, 38, 642-651.	1.0	31
85	Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. Frontiers in Immunology, 2019, 10, 1026.	2.2	31
86	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
87	Altered Expression of TNF-α Signaling Pathway Proteins in Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1658-1666.	1.0	30
88	Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus. Oncology, 2013, 85, 235-240.	0.9	30
89	Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study. Clinical Rheumatology, 2017, 36, 2667-2671.	1.0	30
90	Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus. Journal of Parenteral and Enteral Nutrition, 2011, 35, 198-208.	1.3	29

#	Article	IF	Citations
91	Clinical and Serologic Factors Associated with Lupus Pleuritis. Journal of Rheumatology, 2010, 37, 747-753.	1.0	28
92	Molecular Markers of Injury in Kidney Biopsy Specimens of Patients with Lupus Nephritis. Journal of Molecular Diagnostics, 2011, 13, 143-151.	1.2	28
93	Systemic Autoimmune Rheumatic Disease Prevalence in Canada: Updated Analyses Across 7 Provinces. Journal of Rheumatology, 2014, 41, 673-679.	1.0	28
94	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. Journal of Rheumatology, 2014, 41, 875-880.	1.0	28
95	Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: A Reliable Index for Measuring Improvement in Disease Activity. Journal of Rheumatology, 2011, 38, 868-873.	1.0	27
96	A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Research and Therapy, 2016, 18, 218.	1.6	27
97	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 393-396.	1.0	27
98	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
99	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 29.	1.6	27
100	Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thrombosis and Haemostasis, 2003, 90, 108-15.	1.8	27
101	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
102	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). PLoS ONE, 2017, 12, e0189840.	1.1	26
103	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2211-2219.	6.7	25
104	Fc $\hat{I}^3$ RIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood, 2020, 136, 2933-2945.	0.6	25
105	Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thrombosis and Haemostasis, 2009, 101, 100-107.	1.8	25
106	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2274-2286.	1.9	24
107	Rheumatoid arthritis prevalence in Quebec. BMC Research Notes, 2014, 7, 937.	0.6	23
108	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23

#	Article	IF	CITATIONS
109	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
110	Transitioning to Employment with a Rheumatic Disease: The Role of Independence, Overprotection, and Social Support. Journal of Rheumatology, 2014, 41, 2386-2394.	1.0	21
111	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
112	Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thrombosis and Haemostasis, 2004, 92, 1312-1319.	1.8	20
113	Ten-year Absolute Fracture Risk and Hip Bone Strength in Canadian Women with Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 1378-1384.	1.0	20
114	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547.	1.0	19
115	Longitudinal Evolution of Risk of Coronary Heart Disease in Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 968-973.	1.0	18
116	Mitochondria drive NETosis and inflammation in SLE. Nature Reviews Rheumatology, 2016, 12, 195-196.	3.5	18
117	Work factors are associated with workplace activity limitations in systemic lupus erythematosus. Rheumatology, 2014, 53, 2044-2052.	0.9	17
118	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
119	Development of the Lupus Interactive Navigator as an Empowering Web-Based eHealth Tool to Facilitate Lupus Management: Users Perspectives on Usability and Acceptability. JMIR Research Protocols, 2016, 5, e44.	0.5	17
120	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. Arthritis Care and Research, 2017, 69, 124-132.	1.5	16
121	The Use of Micronutrient Supplements Is Not Associated with Better Quality of Life and Disease Activity in Canadian Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 87-90.	1.0	15
122	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	1.0	15
123	Purpura fulminans and anticardiolipin antibodies in a patient with Grave's disease. Scandinavian Journal of Rheumatology, 2002, 31, 371-373.	0.6	14
124	Thrombovascular Events Affect Quality of Life in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2011, 38, 1017-1019.	1.0	14
125	Familial antiphospholipid syndrome and HLA–DRB gene associations. Arthritis and Rheumatism, 1997, 40, 1907-1908.	6.7	13
126	Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). Lupus, 1999, 8, 606-611.	0.8	13

#	Article	IF	Citations
127	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology, 2016, 56, kew441.	0.9	13
128	The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery. Journal of Rheumatology, 2016, 43, 861-868.	1.0	13
129	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & mp; international networking (APS ACTION) clinical database and repository analysis. Thrombosis Research, 2019, 175, 32-36.	0.8	13
130	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
131	Identification of Mitofusin 1 and Complement Component 1q Subcomponent Binding Protein as Mitochondrial Targets in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 1193-1203.	2.9	13
132	Medication Use in Systemic Lupus Erythematosus. Journal of Rheumatology, 2011, 38, 271-274.	1.0	12
133	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. Journal of Rheumatology, 2018, 45, 1440-1447.	1.0	12
134	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 166-175.	1.0	12
135	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
136	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. Journal of Clinical Epidemiology, 2008, 61, 654-662.	2.4	11
137	Association of autoantibodies to heatâ€shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies. Arthritis and Rheumatism, 2011, 63, 2416-2424.	6.7	11
138	Methodologic Issues in the Validation of Putative Biomarkers and Surrogate Endpoints in Treatment Evaluation for Systemic Lupus Erythematosus. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 108-112.	0.6	10
139	Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decisionâ€Making in Systemic Lupus Erythematosus Treatment?. Arthritis Care and Research, 2022, 74, 1070-1078.	1.5	10
140	Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. Rheumatology, 2011, 50, 799-805.	0.9	9
141	A Hot Spot for Systemic Lupus Erythematosus, but Not for Psoriatic Arthritis, Identified by Spatial Analysis Suggests an Interaction Between Ethnicity and Place of Residence. Arthritis and Rheumatism, 2013, 65, 1579-1585.	6.7	9
142	Job Accommodations Availability and Utilization Among People With Lupus: An Examination of Workplace Activity Limitations and Work Context Factors. Arthritis Care and Research, 2015, 67, 1536-1544.	1.5	9
143	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Journal of Thrombosis and Haemostasis, 2019, 17, 2069-2080.	1.9	9
144	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9

#	Article	IF	Citations
145	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	1.2	9
146	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
147	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€~Registry'). Lupus Science and Medicine, 2022, 9, e000633.	1.1	9
148	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient entered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	1.5	8
149	Challenges of Perceived <scp>Selfâ€Management</scp> in Lupus. Arthritis Care and Research, 2022, 74, 1113-1121.	1.5	8
150	Enhanced myelopoiesis and aggravated arthritis in S100a8-deficient mice. PLoS ONE, 2019, 14, e0221528.	1.1	7
151	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
152	The Purinergic Receptor P2X4 Promotes Th17 Activation and the Development of Arthritis. Journal of Immunology, 2022, 208, 1115-1127.	0.4	7
153	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	1.5	7
154	Alpha2beta1 Integrin (VLA-2) Protects Activated Human Effector T Cells From Methotrexate-Induced Apoptosis. Frontiers in Immunology, 2018, 9, 2269.	2.2	6
155	Development and Acceptability of a Patient Decision Aid for Pain Management in Juvenile Idiopathic Arthritis: The JIA Option Map. Patient, 2020, 13, 719-728.	1.1	5
156	lgGâ€aggregates rapidly upregulate FcgRI expression at the surface of human neutrophils in a FcgRIIâ€dependent fashion: A crucial role for FcgRI in the generation of reactive oxygen species. FASEB Journal, 2020, 34, 15208-15221.	0.2	5
157	Pilot study of anti-mitochondrial antibodies in antiphospholipid syndrome. Lupus, 2020, 29, 1623-1629.	0.8	5
158	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). Arthritis Research and Therapy, 2020, 22, 132.	1.6	5
159	Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus. Lupus Science and Medicine, 2022, 9, e000605.	1.1	5
160	Measuring the Impact of <scp>MyLupusGuide</scp> in Canada: Results of a Randomized Controlled Study. Arthritis Care and Research, 2023, 75, 529-539.	1.5	4
161	Sharing Ongoing Care with Primary Care Physicians Opens Up Opportunity for Timelier and Earlier Care by Rheumatologists for Patients with New Inflammatory Polyarthritis. Journal of Rheumatology, 2018, 45, 266-273.	1.0	3
162	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3

#	Article	IF	CITATIONS
163	Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. Joint Bone Spine, 2015, 82, 373-375.	0.8	2
164	Toward the Development of a Lupus Interactive Navigator to Facilitate Patients and Their Health Care Providers in the Management of Lupus: Results of Web-Based Surveys. JMIR Research Protocols, 2014, 3, e65.	0.5	2
165	Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study. BMC Rheumatology, 2021, 5, 52.	0.6	1
166	CS-36â€Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
167	Response to Middleton KR et als. Yoga and SLE. Complementary Therapies in Medicine, 2019, 43, 311.	1.3	0
168	P98â€Neutrophils in lupus: a new phenotype. , 2020, , .		0
169	1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0